Hilleman 2025-2030

Hilleman Laboratories translates early discoveries to make vaccines for infectious diseases and improve global health.

Established in 2009, Hilleman Laboratories has a public health mission to develop affordable vaccines and biologics against infectious diseases prevalent in low- and middle-income countries.

Their expertise in end-to-end product development is targeted at creating novel vaccines and biologics in areas of high unmet need as well as adapting existing vaccines and biologics with more effective delivery tools to meet challenging environments in developing countries.

They also seek to collaborate with local, regional, and global partners and stakeholders, including policymakers and governments, to facilitate wider, affordable access to life-saving vaccines and biologics.